Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280494635> ?p ?o ?g. }
- W4280494635 endingPage "103705" @default.
- W4280494635 startingPage "103705" @default.
- W4280494635 abstract "Single-agent Talimogene Laherparepvec (T-VEC) was developed for treatment of unresectable and injectable stage III-IV melanoma. Since its approval and reimbursement, studies have reported varying response rates. The purpose of this systematic review and meta-analysis was to investigate the efficacy and safety of T-VEC. Of 341 publications that were identified, eight studies with a total of 642 patients were included. In patients with stage IIIB-IVM1a, the pooled complete- and overall response rate (CRR and ORR) were 41% and 64%, respectively. In patients with stage IIIB-IVM1c, the pooled CRR and ORR were 30% and 44%, respectively. In patients with stage IVM1b and IVM1c, the pooled CRR and ORR were 4% and 9%, respectively. Adverse events (AEs) were seen in 41-100% of all patients and 0-11% of AEs were severe. In conclusion, single agent T-VEC achieves the highest response rates in patients with early metastatic melanoma and is well-tolerated with generally only mild toxicities." @default.
- W4280494635 created "2022-05-22" @default.
- W4280494635 creator A5000559108 @default.
- W4280494635 creator A5007717740 @default.
- W4280494635 creator A5009141072 @default.
- W4280494635 creator A5017388943 @default.
- W4280494635 creator A5019573174 @default.
- W4280494635 creator A5043416056 @default.
- W4280494635 creator A5044990437 @default.
- W4280494635 creator A5045238785 @default.
- W4280494635 creator A5063155328 @default.
- W4280494635 creator A5072403971 @default.
- W4280494635 creator A5073219721 @default.
- W4280494635 creator A5077780102 @default.
- W4280494635 creator A5078183093 @default.
- W4280494635 date "2022-07-01" @default.
- W4280494635 modified "2023-10-01" @default.
- W4280494635 title "Single agent Talimogene Laherparepvec for stage IIIB-IVM1c melanoma patients: A systematic review and meta-analysis" @default.
- W4280494635 cites W2019607817 @default.
- W4280494635 cites W2086591619 @default.
- W4280494635 cites W2097995306 @default.
- W4280494635 cites W2109274792 @default.
- W4280494635 cites W2112121482 @default.
- W4280494635 cites W2119605658 @default.
- W4280494635 cites W2126930838 @default.
- W4280494635 cites W2133075384 @default.
- W4280494635 cites W2152897456 @default.
- W4280494635 cites W2265285917 @default.
- W4280494635 cites W2298802783 @default.
- W4280494635 cites W2417616718 @default.
- W4280494635 cites W2473956396 @default.
- W4280494635 cites W2501481893 @default.
- W4280494635 cites W2736194991 @default.
- W4280494635 cites W2750781282 @default.
- W4280494635 cites W2752227448 @default.
- W4280494635 cites W2757427979 @default.
- W4280494635 cites W2763265527 @default.
- W4280494635 cites W2897056135 @default.
- W4280494635 cites W2904494044 @default.
- W4280494635 cites W2913700843 @default.
- W4280494635 cites W2914448678 @default.
- W4280494635 cites W2948662515 @default.
- W4280494635 cites W2954618642 @default.
- W4280494635 cites W2967262233 @default.
- W4280494635 cites W2975424845 @default.
- W4280494635 cites W3006513742 @default.
- W4280494635 cites W3043703771 @default.
- W4280494635 cites W3115367908 @default.
- W4280494635 cites W3118615836 @default.
- W4280494635 cites W3122380146 @default.
- W4280494635 cites W3132769423 @default.
- W4280494635 cites W3203855951 @default.
- W4280494635 doi "https://doi.org/10.1016/j.critrevonc.2022.103705" @default.
- W4280494635 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35569723" @default.
- W4280494635 hasPublicationYear "2022" @default.
- W4280494635 type Work @default.
- W4280494635 citedByCount "3" @default.
- W4280494635 countsByYear W42804946352022 @default.
- W4280494635 countsByYear W42804946352023 @default.
- W4280494635 crossrefType "journal-article" @default.
- W4280494635 hasAuthorship W4280494635A5000559108 @default.
- W4280494635 hasAuthorship W4280494635A5007717740 @default.
- W4280494635 hasAuthorship W4280494635A5009141072 @default.
- W4280494635 hasAuthorship W4280494635A5017388943 @default.
- W4280494635 hasAuthorship W4280494635A5019573174 @default.
- W4280494635 hasAuthorship W4280494635A5043416056 @default.
- W4280494635 hasAuthorship W4280494635A5044990437 @default.
- W4280494635 hasAuthorship W4280494635A5045238785 @default.
- W4280494635 hasAuthorship W4280494635A5063155328 @default.
- W4280494635 hasAuthorship W4280494635A5072403971 @default.
- W4280494635 hasAuthorship W4280494635A5073219721 @default.
- W4280494635 hasAuthorship W4280494635A5077780102 @default.
- W4280494635 hasAuthorship W4280494635A5078183093 @default.
- W4280494635 hasBestOaLocation W42804946352 @default.
- W4280494635 hasConcept C121608353 @default.
- W4280494635 hasConcept C126322002 @default.
- W4280494635 hasConcept C141071460 @default.
- W4280494635 hasConcept C143998085 @default.
- W4280494635 hasConcept C146357865 @default.
- W4280494635 hasConcept C151730666 @default.
- W4280494635 hasConcept C197934379 @default.
- W4280494635 hasConcept C2776694085 @default.
- W4280494635 hasConcept C2777658100 @default.
- W4280494635 hasConcept C3019096185 @default.
- W4280494635 hasConcept C502942594 @default.
- W4280494635 hasConcept C71924100 @default.
- W4280494635 hasConcept C82210918 @default.
- W4280494635 hasConcept C86803240 @default.
- W4280494635 hasConcept C95190672 @default.
- W4280494635 hasConceptScore W4280494635C121608353 @default.
- W4280494635 hasConceptScore W4280494635C126322002 @default.
- W4280494635 hasConceptScore W4280494635C141071460 @default.
- W4280494635 hasConceptScore W4280494635C143998085 @default.
- W4280494635 hasConceptScore W4280494635C146357865 @default.
- W4280494635 hasConceptScore W4280494635C151730666 @default.
- W4280494635 hasConceptScore W4280494635C197934379 @default.
- W4280494635 hasConceptScore W4280494635C2776694085 @default.
- W4280494635 hasConceptScore W4280494635C2777658100 @default.